{
  "id": 17886977,
  "title": "Nurix Therapeutics chief legal officer sells $103,986 in shares",
  "url": "https://urgent.news/2026/11/03/nurix-therapeutics-chief-legal-officer-sells-103-986-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-03T01:15:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/nurix-therapeutics-chief-legal-officer-sells-103986-in-shares-93CH-4993328"
  },
  "original_language": "en",
  "account": "On October 30, 2026, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), sold 3,957 shares of the company's common stock, totaling $103,986 in revenue. The sale occurred in three price segments, ranging from $26.135 to $26.42 per share, with a weighted average sale price of $26.2791. The transactions were made to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and were not discretionary trades by Ms. Ring. Simultaneously, she purchased 10,182 shares of Nurix Therapeutics common stock through the vesting of RSUs, which amounted to a total of 15,335 shares held directly by Ms. Ring.\n\nFollowing the sale, Ms. Ring's shares were valued at the company's current market price of $26.42 per share. The company's stock has shown an impressive 104% return over the past year, outperforming broader market indices. InvestingPro analysts assessed Nurix Therapeutics as undervalued at current levels, citing an \"EXCELLENT\" financial health score for the company. Additional ProTips and Fair Value analysis are available on the InvestingPro platform for investors.\n\nIn separate developments, Nurix Therapeutics reported its third-quarter fiscal 2026 results, achieving a net gain of $4.73 per share and generating $673.1 million in collaboration and license revenue. Research and development expenses amounted to $79.3 million, while selling, general, and administrative expenses were $34.4 million. Following the announcement, several analysts raised their price targets for Nurix. H.C. Wainwright increased its price target to $36, while Stifel raised its target to $41, both maintaining Buy ratings. Conversely, RBC Capital reduced its price target to $35 but retained an Outperform rating. Truist Securities lowered its price target to $33, yet continued to express confidence in Nurix's ongoing progress. These divergent analyst opinions underscore the ongoing interest in Nurix Therapeutics and its future prospects.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}